Recent years have seen a remarkable expansion of therapeutic options available for many
forms of cancer. Evidence for the efficacy of these treatments have mainly come from …

In Europe, most of the cancer clinical research dedicated to therapeutic innovations aims
primarily at regulatory approval. Once an anticancer drug enters the common market, each …

Objectives Breakthrough innovation in oncology is commonly considered to be a substantial
increase in overall survival (OS) above specific thresholds. However, this growing emphasis …

There is an increasing demand for real world evidence. The shift towards relative
effectiveness assessment increasingly based on real world data is a natural consequence of …

Simple Summary Drug repurposing strategies utilize drugs, already approved by regulatory
authorities, to test their efficacy against different diseases. While this approach is …

As health care costs are constantly rising and governments are reforming their healthcare
systems there is an urgent need to reshape the European clinical research landscape. To …

Many of the recent advances that have been made in cancer care have been, although
arguably important, relatively modest. Sometimes, however, these modest, incremental …

Efforts to unravel the complex biology that is necessary to develop new therapies best suited
for an individual with cancer are at a crossroads with a strained health care system and an …

Excitement about the dramatic increase in potential successful anticancer medicines in
recent years is hampered by the high costs involved as well as the length of time traditional …

Highlights•New discoveries are driving advances in our understanding of cancer and its
evolution.•But progress has been uneven and new drugs are difficult for healthcare systems …